You searched for "disease"
Retinal Pharmacotherapeutics (Developments in Ophthalmology)
Retinal Pharmacotherapeutics is volume 55 in the ‘Developments in Ophthalmology’ series released by Karger. As the name of the series suggests it aims to explore current and future developments in retinal therapeutics. The book itself is split into six main...
Elevated risk of mood disorders after recurrent retinal detachment
1 December 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Epidemiology, Gender, Major depression disorder, Mood disorder, Retinal detachment
This study was aimed to investigate the risk of mood disorders in patients who experienced retinal detachment (RD) by using the National Health Insurance Research Database in Taiwan. A total of 4129 participants diagnosed with RD and 16,516 non-RD individuals...
Rare eye diseases: progress continues with authorised orphan medicines and breakthrough technologies
1 October 2018
| Rod McNeil
|
EYE - General
An update on the development of orphan medicines, recent regulatory treatment approvals for rare eye conditions and advances in retinal prosthetic technologies for blinding diseases. The prevalence of a rare disease is based usually on a range of estimates and...
Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice
1 February 2015
| Pearse A Keane (Prof), Adnan Tufail
|
EYE - Vitreo-Retinal
The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...
Strengthening the signal: Advancing oculomics research for systemic health insights
4 December 2024
| Mertcan Sevgi, Siegfried Wagner
|
EYE - Imaging
Oculomics, the study of how ocular structure reflects systemic health, is poised to become an integral tool for predicting, triaging, and diagnosing a wide range of diseases. By analysing data from the eye, particularly the retina, healthcare providers can gain...
Three years of experience with quantiferon-TB Gold Testing in patients with uveitis
1 April 2015
| Nikolaos D Georgakarakos
|
EYE - Vitreo-Retinal
Quantiferon-TB Gold is a new alternative to the tuberculin skin test that utilises synthetic peptides representing M. tuberculosis antigens ESAT-6, CFP-10, TB7.7 and upon incubation with whole blood IFN-γ is released from pre-sensitised T cells and can be measured by...
Can coenzyme Q10 have a protective role in ethambutol-induced retinal ganglion cell toxicity
3 April 2023
| Claire Howard
|
EYE - Neuro-ophthalmology
|
Ethambutol, coenzyme Q10, ethambutol toxic optic neuropathy, retinal ganglion cells, tuberculosis
Tuberculosis (TB) is one of the most prevalent infectious diseases, especially in developing or low- income countries. Ethambutol is a widely used drug to treat TB. Ethambutol can cause visual disturbance including ethambutol toxic optic neuropathy (ETON). ETON is one...
An interview with Professor John Forrester
2 December 2019
| Hari Kaneshayogan
|
EYE - General
What made you choose ophthalmology as a career and how did your interest in academia develop? During Medical School at Glasgow University, I was getting progressively disillusioned with the career options while my colleagues and friends all seemed to quickly...
In conversation with John Forrester
2 December 2019
| Hari Kaneshayogan
|
EYE - General
What made you choose ophthalmology as a career and how did your interest in academia develop? During Medical School at Glasgow University, I was getting progressively disillusioned with the career options while my colleagues and friends all seemed to quickly...
Case series of posterior scleritis
This report aimed to facilitate the correct diagnosis of posterior scleritis, a condition which is usually overlooked or misdiagnosed. Electronic health records of 31 patients with posterior scleritis were analysed and compared to a group with isolated anterior scleritis of...
Nanoparticle administration of latanoprost
1 December 2013
| Graham Wallace
|
EYE - Glaucoma
Glaucoma is a progressive optic neuropathy characterised by increased ocular pressure and loss of retinal ganglion cells. Conventional drug therapy with eye drops to reduce intraocular pressure (IOP) has variable bioavailability and can lead to ocular surface disease. In this...
In conversation with Dr Monicah Bitok, Global Inclusive Eye Health Advisor (CBM)
22 April 2022
|
EYE - General
Eye News spoke to Dr Monicah Bitok, Global Inclusive Eye Health Advisor with the Christian Blind Mission (CBM), about the rise in diabetes-related preventable blindness, systemic ophthalmic changes in low- and middle-income countries, and the impacts of a COVID-19-induced backlog...
